CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer

Running, not enrolling · Phase 2

Conditions studied: Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer

In brief

This is a single arm, phase II trial of combined neoadjuvant platinum doublet chemotherapy plus durvalumab followed by surgery, postoperative radiation and adjuvant durvalumab for 13 cycles for patients with potentially resectable stage IIIA and IIIB (T1-3, N2) NSCLC (per the 8th International Association for the Study of Lung Cancer classification). The primary objective of this study is to increase N2 nodal clearance (N2NC) to 50% or greater for combined platinum doublet chemotherapy with durvalumab induction therapy from historical rate of 30% for platinum doublet chemotherapy alone in patients with potentially resectable stage IIIA/B (N2) NSCLC.

Key facts

Study ID

NCT04062708

Run by

Alliance Foundation Trials, LLC.

People needed

38

Starts

2021-03-10

Expected to finish

2026-07-01

Last updated by the study team

2025-07-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients who are at least 18 years of age.
• Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1.
• Life expectancy of at least 12 weeks.
• Patients with potentially resectable IIIA/B (T1-3, N2) NSCLC (per the 8th International Association for the Study of Lung Cancer classification) who are candidates for surgery with intent of R0 resection. Invasive T3 disease (eg, phrenic nerve, pericardium, chest wall other than Pancoast superior sulcus) may be included if the surgeon and study team deem it to be resectable. T4 disease per AJCC 8th edition staging system is excluded given the lack of benefit of surgery in T4N2.
• Patients must be evaluated by a thoracic surgeon within 4 weeks of registration.
• Operability is defined as having adequate pulmonary, cardiac, renal, nutritional, musculoskeletal, neurologic, and cognitive capacity to undergo major pulmonary resection with acceptable morbidity and mortality.
• N2 nodes must be discrete (ie, not invading surrounding structures) and less than 3 cm in maximum diameter.
• Measurable disease according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1).
• Pathologically proven N2 disease within 4 weeks of registration. PET/CT positivity in the ipsilateral mediastinal nodes will not be sufficient to establish N2 nodal status. Mediastinal lymph node sampling biopsy is required pre-operatively by at least one of the following:
• Endobronchial Ultrasound Transbronchial Needle Aspiration (EBUS-TBNA);
• Mediastinoscopy;
• Mediastinotomy (Chamberlain procedure);
• Endoscopic ultrasound guided node aspiration (EUS);
• Video-assisted thoracoscopy; OR
• Fine needle aspiration by image guidance.
• Endobronchial ultrasound (EBUS) or mediastinoscopy or other tissue sampling (at least 2 stations must be biopsied, with at least one station positive for N2 disease). If there are any mediastinal nodes suspicious by CT (>1.5 cm) or PET in N3 stations, they must be biopsied. If biopsy proven involvement in an N3 station, the patient is excluded.
• Mediastinal nodal biopsy or aspiration can only be omitted in the special circumstance in which ALL of the following are true:
• The tumor is left sided;
• The only mediastinal nodal involvement is a node visible in the AP (level 5) region on CT scan;
• Distinct primary tumor separate from the nodes; AND
• Biopsy proven non-small cell histology from the primary tumor.
• No prior history of thoracic radiation.
• Organ and marrow function definitions (example below)
• leukocytes ≥3,000/mcL
• absolute neutrophil count ≥1,500/mcL

You may not qualify if…

• Any prior treatment for NSCLC.
• Prior thoracic radiation.
• Patients with ≥Grade 2 peripheral neuropathy.
• Any active or history of autoimmune disease (including any history of inflammatory bowel disease) or history of a syndrome that required systemic steroids or immunosuppressive medications, except for patients with vitiligo or resolved childhood asthma/atopy.
• Patients requiring systemic treatment with either corticosteroids (>10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses <10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.
• Patients with previous malignancies (except nonmelanoma skin cancers, in situ bladder, gastric, breast, colon or cervical cancers/dysplasia) are excluded unless a complete remission was achieved at least 2 years prior to study entry and no additional therapy is required or anticipated to be required during the study period.
• History of solid organ transplant.
• N3 nodal disease.
• Mixed small cell/NSCLC will be excluded.
• Pregnant or breastfeeding.
• History of allogenic organ transplantation.
• Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [eg, colitis or Crohn's disease], active diverticulitis with the exception of diverticulosis, systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc]). The following are exceptions to this criterion:
• Patients with vitiligo or alopecia.
• Patients with hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement.
• Any chronic skin condition that does not require systemic therapy.
• Patients without active disease in the last 5 years may be included but only after consultation with the study physician.
• Patients with celiac disease controlled by diet alone.
• Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent.
• Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥470 ms calculated.

Where it is running

• NorthWestern University — Chicago, Illinois, United States
• University of Chicago Medical Center — Chicago, Illinois, United States
• Massachusetts General Hospital — Boston, Massachusetts, United States
• Brigham and Women's Hospital — Boston, Massachusetts, United States
• Lowell General Hospital — Lowell, Massachusetts, United States
• SUNY Upstate Medical University — Syracuse, New York, United States
• Baptist Cancer Center — Memphis, Tennessee, United States
• University of Texas MD Anderson Cancer Center — Houston, Texas, United States
• University of Virginia Health System — Charlottesville, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.